Faculty of Pharmaceutical Sciences, Chulalongkorn University

Assetwise (SET: ASW) Joins TOKYO TATEMONO in 2nd Joint Venture, Targeting Campus Condo Market near Burapha University

Retrieved on: 
Thursday, August 3, 2023
Faculty, Tokyo Tatemono, Sky Campus, ESTA, Happiness, DNA, High-speed rail in Thailand, Housing, The Hive, Singapore, Pharmacy, Information and Public Relations Department, Bihar, Parent, Genomics, SET, Sale, Student, Kaveh the Blacksmith, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Burapha University, Growth, EEC, Suvarnabhumi Airport, ASW, Don Mueang International Airport, U-Tapao International Airport, Property management, Tourism

Most recently, ASW entered into a joint venture with Tokyo Tatemono Asia Pte.

Key Points: 
  • Most recently, ASW entered into a joint venture with Tokyo Tatemono Asia Pte.
  • This successful collaboration further solidifies ASW's leadership in the Campus Condo market, focusing on condominiums located near educational institutions, with ASW holding 51% of the shares and Tokyo Tatemono holding 49%.
  • "This joint venture marks the second project between our company and Tokyo Tatemono, working together to create residential solutions that cater to the lifestyle of the new generation.
  • It reaffirms the confidence Tokyo Tatemono has in our company as a leader in the Campus Condo market and the lifestyle-oriented real estate market in Thailand.

GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

Retrieved on: 
Wednesday, April 19, 2023
Faculty, Shareholder, CET, Pharmacy, April 19, Internet, Faculty of Pharmaceutical Sciences, Chulalongkorn University, PARC, Documentation, Patient, Bulletin, Chronic liver disease, Finance, Euronext

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 19, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 19, 2023 French legal announcements bulletin n°47 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 24, 2023, at 10:00am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

Key Points: 
  • Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 19, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 19, 2023 French legal announcements bulletin n°47 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 24, 2023, at 10:00am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
  • All documentation regarding this Shareholders’ Meeting will be available to shareholders in accordance with existing regulations, and will be available on the Company’s website, in the Financials section under the Shareholders Meeting tab ( https://ir.genfit.com/financial-information/shareholders-meeting ).
  • For this 2023 Combined General Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform.
  • A tutorial to familiarize shareholders with this online voting platform will be made available in the same section of the website as soon as the platform is opened.

GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents

Retrieved on: 
Wednesday, April 20, 2022
Nasdaq, Liver disease, Pharmacy, Internet, Cholangiocarcinoma, Primary biliary cholangitis, LabCorp, U.S. Securities and Exchange Commission, PARC, Documentation, Chapter Two, Research, Cirrhosis, Annual report, NASH, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Private Securities Litigation Reform Act, Patient, Loos, Biomarker, Bulletin, PBC, Review, Company, United Kingdom, Chronic liver disease, FRANCE, SEC, Faculty, History, Investor, Safety, Industry, Acquisition, AMF, Pharmaceutical industry, ACLF, Euronext

For this 2022 Combined General Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform.

Key Points: 
  • For this 2022 Combined General Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform.
  • GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs.
  • GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
  • In 2021, GENFIT signed an exclusive licensing agreement with IPSEN to develop, manufacture and commercialize elafibranor in PBC and other indications.

LifeLabs partners with UBC on Drone Transport Initiative to support access to essential health services for BC First Nations communities

Retrieved on: 
Monday, January 24, 2022
TD, FLT, Technology, Research, UBC Faculty of Medicine, Health, Fort Fraser, Canada, GLOBE, COVID-19, DDC, River, Science, Partnership, No, CEO, Faculty, Student, DTI, Faculty of Pharmaceutical Sciences, Chulalongkorn University, UBC, Software, Government, First Nations, First Nations Health Authority, Panic! at the Disco, Leadership, Rural health, OMERS, Pharmacy, Pharmacist, Software as a service, MD, Laboratory, Life, Transport, University, Beekeeping, Medicine, Rural area, Medicine

Were proud to support such an important initiative that will help provide greater access to essential health care services for First Nations communities, said Charles Brown, President and CEO of LifeLabs.

Key Points: 
  • Were proud to support such an important initiative that will help provide greater access to essential health care services for First Nations communities, said Charles Brown, President and CEO of LifeLabs.
  • New technologies such as drones can present opportunities to deliver health services closer to home, improving accessibility to certain medical support for people in remote and rural communities.
  • Many rural and remote First Nations communities have unequal access to health care due to factors such as transportation constraints and challenges with recruiting and retaining health care providers.
  • LifeLabs is proud to support the Drone Transport Initiative, which will help advance our knowledge for the future use of drone technology to transport clinical materials and samples for lab testing.